| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England journal of medicine 383 (27), 2603-2615, 2020 | 16229 | 2020 |
| Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 383 (25), 2439-2450, 2020 | 2858 | 2020 |
| Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... Nature 586 (7830), 589-593, 2020 | 1859 | 2020 |
| Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months SJ Thomas, ED Moreira Jr, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... New England Journal of Medicine 385 (19), 1761-1773, 2021 | 1542 | 2021 |
| Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents RW Frenck Jr, NP Klein, N Kitchin, A Gurtman, J Absalon, S Lockhart, ... New England Journal of Medicine 385 (3), 239-250, 2021 | 1076 | 2021 |
| Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age EB Walter, KR Talaat, C Sabharwal, A Gurtman, S Lockhart, GC Paulsen, ... New England Journal of Medicine 386 (1), 35-46, 2022 | 652 | 2022 |
| Homologous and heterologous Covid-19 booster vaccinations RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, HM El Sahly, ... New England Journal of Medicine 386 (11), 1046-1057, 2022 | 567 | 2022 |
| Helicobacter in the developing world RW Frenck Jr, J Clemens Microbes and infection 5 (8), 705-713, 2003 | 502 | 2003 |
| SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3 AR Falsey, RW Frenck Jr, EE Walsh, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 385 (17), 1627-1629, 2021 | 399 | 2021 |
| Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses GY Melmed, AF Ippoliti, KA Papadakis, TT Tran, JL Birt, SK Lee, ... Official journal of the American College of Gastroenterology| ACG 101 (8 …, 2006 | 391 | 2006 |
| Impact of illness and non-combat injury during Operations Iraqi Freedom and Enduring Freedom (Afghanistan) JW Sanders, SD Putnam, C Frankart, RW Frenck, MR Monteville, ... American Journal of Tropical Medicine and Hygiene 73 (4), 713, 2005 | 327 | 2005 |
| Norovirus vaccine against experimental human GII. 4 virus illness: a challenge study in healthy adults DI Bernstein, RL Atmar, GM Lyon, JJ Treanor, WH Chen, X Jiang, J Vinjé, ... The Journal of infectious diseases 211 (6), 870-878, 2015 | 299 | 2015 |
| Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease GY Melmed, N Agarwal, RW Frenck, AF Ippoliti, P Ibanez, KA Papadakis, ... Official journal of the American College of Gastroenterology| ACG 105 (1 …, 2010 | 231 | 2010 |
| Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age RN Greenberg, A Gurtman, RW Frenck, C Strout, KU Jansen, J Trammel, ... Vaccine 32 (20), 2364-2374, 2014 | 226 | 2014 |
| Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following … LA Jackson, A Gurtman, M van Cleeff, RW Frenck, J Treanor, KU Jansen, ... Vaccine 31 (35), 3594-3602, 2013 | 214 | 2013 |
| RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study EE Walsh, R Frenck, AR Falsey, N Kitchin, J Absalon, A Gurtman, ... Medrxiv, 2020.08. 17.20176651, 2020 | 193 | 2020 |
| Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children RW Frenck Jr, I Nakhla, Y Sultan, SB Bassily, YF Girgis, J David, TC Butler, ... Clinical infectious diseases 31 (5), 1134-1138, 2000 | 193 | 2000 |
| Pathogenicity and Convalescent Excretion of Campylobacter in Rural Egyptian Children MR Rao, AB Naficy, SJ Savarino, R Abu-Elyazeed, TF Wierzba, ... American journal of epidemiology 154 (2), 166-173, 2001 | 183 | 2001 |
| Predicting susceptibility to norovirus GII. 4 by use of a challenge model involving humans R Frenck, DI Bernstein, M Xia, P Huang, W Zhong, S Parker, M Dickey, ... The Journal of infectious diseases 206 (9), 1386-1393, 2012 | 167 | 2012 |
| Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance NI Girgis, T Butler, RW Frenck, Y Sultan, FM Brown, D Tribble, R Khakhria Antimicrobial agents and chemotherapy 43 (6), 1441-1444, 1999 | 165 | 1999 |
